A panel of six human lung cancer cell lines bearing activating mutations in EGFR was tested for growth sensitivity to the 3rd generation TKI, osimertinib, and representative dose–response curves are shown in Supplementary Fig. S1. This evidence concerns the gene EGFR and lung carcinoma.